Evidence map›Paper›PMID 39730470›Full record

ArticleScientific reports2024

Longitudinal analysis of SARS-CoV-2 IgG antibody durability in Puerto Rico.

Zachary J Madewell, Nathan E Graff, Velma K Lopez, Dania M Rodriguez, Joshua M Wong, Panagiotis Maniatis, Freddy A Medina, Jorge L Muñoz, Melissa Briggs-Hagen, Laura E Adams and 3 more

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Zachary J MadewellDivision of Vector-Borne Diseases, Centers for Disease Control and Prevention, San Juan, Puerto Rico. ock0@cdc.gov.
Nathan E GraffCoronavirus and Other Respiratory Viruses Division, Centers for Disease Control and Prevention, Atlanta, Georgia.
Velma K LopezDivision of Vector-Borne Diseases, Centers for Disease Control and Prevention, San Juan, Puerto Rico.
Dania M RodriguezDivision of Vector-Borne Diseases, Centers for Disease Control and Prevention, San Juan, Puerto Rico.
Joshua M WongDivision of Vector-Borne Diseases, Centers for Disease Control and Prevention, San Juan, Puerto Rico.
Panagiotis ManiatisDivision of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
Freddy A MedinaDivision of Vector-Borne Diseases, Centers for Disease Control and Prevention, San Juan, Puerto Rico.
Jorge L MuñozDivision of Vector-Borne Diseases, Centers for Disease Control and Prevention, San Juan, Puerto Rico.
Melissa Briggs-HagenCoronavirus and Other Respiratory Viruses Division, Centers for Disease Control and Prevention, Atlanta, Georgia.
Laura E AdamsDivision of Vector-Borne Diseases, Centers for Disease Control and Prevention, San Juan, Puerto Rico.
Vanessa Rivera-AmillPonce Health Sciences University/Ponce Research Institute, Ponce, Puerto Rico.
Gabriela Paz-BaileyDivision of Vector-Borne Diseases, Centers for Disease Control and Prevention, San Juan, Puerto Rico.
Chelsea G MajorDivision of Vector-Borne Diseases, Centers for Disease Control and Prevention, San Juan, Puerto Rico.

Funding

CDC HHS U01CK000580NCEZID CDC HHS U01 CK000580
6 · The paper itself

Abstract

Understanding the dynamics of antibody responses following vaccination and SARS-CoV-2 infection is important for informing effective vaccination strategies and other public health interventions. This study investigates SARS-CoV-2 antibody dynamics in a Puerto Rican cohort, analyzing how IgG levels vary by vaccination status and previous infection. We assess waning immunity and the distribution of hybrid immunity with the aim to inform public health strategies and vaccination programs in Puerto Rico and similar settings. We conducted a prospective, longitudinal cohort study to identify SARS-CoV-2 infections and related outcomes in Ponce, Puerto Rico, from June 2020-August 2022. Participants provided self-collected nasal swabs every week and serum every six months for RT-PCR and IgG testing, respectively. IgG reactivity against nucleocapsid (N) antigens, which generally indicate previous infection, and spike (S1) and receptor-binding domain (RBD) antigens, which indicate history of either infection or vaccination, was assessed using the Luminex Corporation xMAP® SARS-CoV-2 Multi-Antigen IgG Assay. Prior infection was defined by positive RT-PCRs, categorized by the predominant circulating SARS-CoV-2 variant at the event time. Demographic information, medical history, and COVID-19 vaccination history were collected through standardized questionnaires. Of 882 participants included in our analysis, 34.0% experienced at least one SARS-CoV-2 infection, with most (78.7%) occurring during the Omicron wave (December 2021 onwards). SARS-CoV-2 antibody prevalence increased over time, reaching 98.4% by the final serum collection, 67.0% attributable to vaccination alone, 1.6% from infection alone, and 31.4% from both. Regardless of prior infection status, RBD and S1 IgG levels gradually declined following two vaccine doses. A third dose boosted these antibody levels and showed a slower decline over time. N-antibody levels peaked during the Omicron surge and waned over time. Vaccination in individuals with prior SARS-CoV-2 infection elicited the highest and most durable antibody responses. N or S1 seropositivity was associated with lower odds of a subsequent positive PCR test during the Omicron period, with N antibodies showing a stronger association. By elucidating the differential decay of RBD and S1 antibodies following vaccination and the complexities of N-antibody response following infection, this study in a Puerto Rican cohort strengthens the foundation for developing targeted interventions and public health strategies.

Indexed as

Antibodies, ViralCOVID-19Immunoglobulin GSARS-CoV-2AdultAgedCOVID-19 VaccinesFemaleHumansLongitudinal StudiesMaleMiddle AgedProspective StudiesPuerto RicoSpike Glycoprotein, CoronavirusVaccinationAntibodies, ViralCOVID-19 VaccinesImmunoglobulin GSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Antibody dynamicsCaribbeanCOVID-19Humoral immunityOmicronVaccination

Identifiers

PMID39730470
PMCPMC11681247

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.